Natalie Callander, MD, on Selinexor in Myeloma: Triplet Combinations, Dosing, Efficacy

Natalie Callander, MD, of the University of Wisconsin Carbone Cancer Center, discusses a study on selinexor, pomalidomide, and dexamethasone for the treatment of relapsed or refractory multiple myeloma presented at the 66th American Society of Hematology Annual Meeting & Exposition.

“What’s happened in the last few years is using lower doses of selinexor in combination with other agents to look for synergy and exploit the mechanism of action,” Dr. Callander explained.

The study evaluated two doses of selinexor in combination with pomalidomide and dexamethasone: 40 mg per week and 60 mg per week. Compared with patients receiving 60 mg, patients receiving 40 mg of selinexor had less frequent treatment-emergent adverse events, longer duration of response, and higher dose intensity.

“Even in patients who were refractory, the response rates were really exciting,” Dr. Callander said. “We were seeing response rates that were in the seven, eight, nine months and longer, and some complete responses.”